tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CABA Stock Latest News

Cabaletta Bio Updates on Rese-cel Therapy Progress
Company AnnouncementsCabaletta Bio Updates on Rese-cel Therapy Progress
14d ago
8K
CABA
Cabaletta Bio price target lowered to $16 from $25 at H.C. Wainwright
PremiumThe Fly
Cabaletta Bio price target lowered to $16 from $25 at H.C. Wainwright
1M ago
CABA
Cabaletta Bio price target lowered to $2 from $3 at Wells Fargo
PremiumThe Fly
Cabaletta Bio price target lowered to $2 from $3 at Wells Fargo
1M ago
CABA
Cabaletta Bio Reports Progress in Clinical Trials
PremiumCompany Announcements
Cabaletta Bio Reports Progress in Clinical Trials
1M ago
CABA
Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Drive Buy Rating
PremiumRatings
Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Drive Buy Rating
1M ago
CABA
Cabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis
PremiumCompany AnnouncementsCabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis
1M ago
CABA
Cabaletta Bio files $240M mixed securities shelf
Premium
The Fly
Cabaletta Bio files $240M mixed securities shelf
1M ago
CABA
Cabaletta Bio reports Q2 EPS (73c), consensus (61c)
Premium
The Fly
Cabaletta Bio reports Q2 EPS (73c), consensus (61c)
1M ago
CABA
Cabaletta Bio sees cash runway into 2H26
PremiumThe Fly
Cabaletta Bio sees cash runway into 2H26
1M ago
CABA
Cabaletta Bio’s Promising Study on CABA-201 for Myasthenia Gravis: A Potential Game-Changer
PremiumCompany Announcements
Cabaletta Bio’s Promising Study on CABA-201 for Myasthenia Gravis: A Potential Game-Changer
1M ago
CABA
Cabaletta Bio’s RESET-SLE Study: A Promising Step in Lupus Treatment
PremiumCompany Announcements
Cabaletta Bio’s RESET-SLE Study: A Promising Step in Lupus Treatment
2M ago
CABA
Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment
PremiumCompany Announcements
Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment
2M ago
CABA
Cabaletta Bio’s RESET-Myositis Study: A Promising Step in Autoimmune Treatment
PremiumCompany AnnouncementsCabaletta Bio’s RESET-Myositis Study: A Promising Step in Autoimmune Treatment
2M ago
CABA
Cabaletta Bio’s RESET-MG Study: A Promising Step in Myasthenia Gravis Treatment
Premium
Company Announcements
Cabaletta Bio’s RESET-MG Study: A Promising Step in Myasthenia Gravis Treatment
2M ago
CABA
Cabaletta Bio’s RESET-Myositis Study: A Potential Game-Changer in Autoimmune Disease Treatment
Premium
Company Announcements
Cabaletta Bio’s RESET-Myositis Study: A Potential Game-Changer in Autoimmune Disease Treatment
2M ago
CABA
Cabaletta Bio Announces $94 Million Public Offering
PremiumCompany Announcements
Cabaletta Bio Announces $94 Million Public Offering
3M ago
8K
CABA
Promising Clinical Data and Positive Trajectory Support Buy Rating for Cabaletta Bio
PremiumRatings
Promising Clinical Data and Positive Trajectory Support Buy Rating for Cabaletta Bio
3M ago
CABA
Promising Clinical Data from Cabaletta Bio’s RESET Trial Supports Buy Rating
PremiumRatings
Promising Clinical Data from Cabaletta Bio’s RESET Trial Supports Buy Rating
3M ago
CABA
Promising Efficacy and Strategic Advancements: Douglas Tsao’s Buy Rating on Cabaletta Bio
PremiumRatings
Promising Efficacy and Strategic Advancements: Douglas Tsao’s Buy Rating on Cabaletta Bio
3M ago
CABA
Cabaletta presents ‘promising’ results across indications, says H.C. Wainwright
PremiumThe FlyCabaletta presents ‘promising’ results across indications, says H.C. Wainwright
3M ago
CABA
Cabaletta Bio Ends Sales Agreement with TD Securities
Premium
Company Announcements
Cabaletta Bio Ends Sales Agreement with TD Securities
3M ago
8K
CABA
Cabaletta Bio announces offering of common stock, warrants, no amount given
Premium
The Fly
Cabaletta Bio announces offering of common stock, warrants, no amount given
3M ago
CABA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >